Drug Profile
CT 140
Alternative Names: CT-140Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator CisThera
- Class Antibodies
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 06 Sep 2023 CT 140 is still in preclinical trials for Fibrosis in the US (CisThera pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Fibrosis in USA
- 18 Jul 2016 Preclinical trials in Fibrosis in USA (unspecified route)